Tang, Yun-Ping
Gong, Jing-Yu
Setchell, Kenneth D. R.
Zhang, Wujuan
Zhao, Jing
Wang, Jian-She http://orcid.org/0000-0002-5093-6697
Funding for this research was provided by:
the National Natural Science Foundation of China (No. 81570468, No. 81873543)
Article History
Received: 9 November 2020
Accepted: 5 April 2021
First Online: 13 April 2021
Declarations
:
: This article is a retrospective study, so ethical approval was not necessary, and the Jinshan Hospital of Fudan University can offer an exempt ethical statement in support. The study conformed to the ethical guidelines of the Declaration of Helsinki 1975. Informed consent was obtained from the child’s parents before the initiation of CDCA therapy.
: The patient’s parents provided informed written consent for this publication.
: Setchell KDR is a consultant to Retrophin San Diego, United States, and holds minor equity in Asklepion Pharmaceuticals; Wang JS consulted for Shanghai Ethypharm. The other authors declare no conflicts of interest.